[
  {
    "ts": null,
    "headline": "Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump",
    "summary": "Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been dealing with difficult year-over-year comps due to a withering COVID-19 portfolio. Moreover, many of Pfizer’s products, like Eliquis (2027 to 2029) and Ibrance (2027), face “patent cliffs.” That means their time for market exclusivity is",
    "url": "https://finnhub.io/api/news?id=4aa488ac19b07f7b0bec5892050d6a7eb611f188f8318e659fb8bfcc78d845f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743612204,
      "headline": "Potential Stock Woe Ahead as Pfizer (PFE) Riles Donald Trump",
      "id": 133669553,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The pharmaceutical giant, best known for its COVID-19 products (Paxlovid and Comirnaty), Eliquis, and Prevnar, a pneumococcal vaccine, has been dealing with difficult year-over-year comps due to a withering COVID-19 portfolio. Moreover, many of Pfizer’s products, like Eliquis (2027 to 2029) and Ibrance (2027), face “patent cliffs.” That means their time for market exclusivity is",
      "url": "https://finnhub.io/api/news?id=4aa488ac19b07f7b0bec5892050d6a7eb611f188f8318e659fb8bfcc78d845f9"
    }
  },
  {
    "ts": null,
    "headline": "PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo",
    "summary": "The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.",
    "url": "https://finnhub.io/api/news?id=bdff497591b532afed07447fa207f50445bbbe378775d977fa0be861bbef52c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743593820,
      "headline": "PFE Secures EU Nod for Expanded Use of RSV Vaccine Abrysvo",
      "id": 133669560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The latest decision makes Pfizer's Abrysvo the first RSV vaccine approved for use in non-pregnant adults under 50 years of age in the EU.",
      "url": "https://finnhub.io/api/news?id=bdff497591b532afed07447fa207f50445bbbe378775d977fa0be861bbef52c4"
    }
  }
]